Cargando…
Cancer Therapy-Related Cardiovascular Complications in Clinical Practice: Current Perspectives
Cardiovascular (CV) diseases and cancer are the leading causes of death in Europe and the United States. Both diseases have extensive overlap and share common risk factors, symptoms, and outcomes. As the number of patients with both cancer and CV diseases continues to rise, the field of cardio-oncol...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069381/ https://www.ncbi.nlm.nih.gov/pubmed/33924543 http://dx.doi.org/10.3390/jcm10081647 |
_version_ | 1783683223936565248 |
---|---|
author | Bohdan, Michał Kowalczys, Anna Mickiewicz, Agnieszka Gruchała, Marcin Lewicka, Ewa |
author_facet | Bohdan, Michał Kowalczys, Anna Mickiewicz, Agnieszka Gruchała, Marcin Lewicka, Ewa |
author_sort | Bohdan, Michał |
collection | PubMed |
description | Cardiovascular (CV) diseases and cancer are the leading causes of death in Europe and the United States. Both diseases have extensive overlap and share common risk factors, symptoms, and outcomes. As the number of patients with both cancer and CV diseases continues to rise, the field of cardio-oncology is gaining increased attention. A frequent problem during anti-cancer treatment is cardiotoxicity caused by the side-effects of chemo-, immuno-, targeted, and radiation therapies. This problem may manifest as acute coronary syndrome, myocarditis, arrhythmias, or heart failure. Modern cardio-oncology spans many different research areas. While some researchers focus on treating patients that have already developed cardiotoxicity, others aim to identify new methods for preventing cardiotoxicity before, during, and after anti-cancer therapy. Both groups share the common understanding that regular monitoring of cancer patients is the basis for optimal medical treatment. Optimal treatment can only be achieved through close cooperation between cardiologists and oncologists. This review summarizes the current views on cardio-oncology and discusses the cardiotoxicities associated with commonly used chemotherapeutics. |
format | Online Article Text |
id | pubmed-8069381 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80693812021-04-26 Cancer Therapy-Related Cardiovascular Complications in Clinical Practice: Current Perspectives Bohdan, Michał Kowalczys, Anna Mickiewicz, Agnieszka Gruchała, Marcin Lewicka, Ewa J Clin Med Review Cardiovascular (CV) diseases and cancer are the leading causes of death in Europe and the United States. Both diseases have extensive overlap and share common risk factors, symptoms, and outcomes. As the number of patients with both cancer and CV diseases continues to rise, the field of cardio-oncology is gaining increased attention. A frequent problem during anti-cancer treatment is cardiotoxicity caused by the side-effects of chemo-, immuno-, targeted, and radiation therapies. This problem may manifest as acute coronary syndrome, myocarditis, arrhythmias, or heart failure. Modern cardio-oncology spans many different research areas. While some researchers focus on treating patients that have already developed cardiotoxicity, others aim to identify new methods for preventing cardiotoxicity before, during, and after anti-cancer therapy. Both groups share the common understanding that regular monitoring of cancer patients is the basis for optimal medical treatment. Optimal treatment can only be achieved through close cooperation between cardiologists and oncologists. This review summarizes the current views on cardio-oncology and discusses the cardiotoxicities associated with commonly used chemotherapeutics. MDPI 2021-04-13 /pmc/articles/PMC8069381/ /pubmed/33924543 http://dx.doi.org/10.3390/jcm10081647 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Bohdan, Michał Kowalczys, Anna Mickiewicz, Agnieszka Gruchała, Marcin Lewicka, Ewa Cancer Therapy-Related Cardiovascular Complications in Clinical Practice: Current Perspectives |
title | Cancer Therapy-Related Cardiovascular Complications in Clinical Practice: Current Perspectives |
title_full | Cancer Therapy-Related Cardiovascular Complications in Clinical Practice: Current Perspectives |
title_fullStr | Cancer Therapy-Related Cardiovascular Complications in Clinical Practice: Current Perspectives |
title_full_unstemmed | Cancer Therapy-Related Cardiovascular Complications in Clinical Practice: Current Perspectives |
title_short | Cancer Therapy-Related Cardiovascular Complications in Clinical Practice: Current Perspectives |
title_sort | cancer therapy-related cardiovascular complications in clinical practice: current perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069381/ https://www.ncbi.nlm.nih.gov/pubmed/33924543 http://dx.doi.org/10.3390/jcm10081647 |
work_keys_str_mv | AT bohdanmichał cancertherapyrelatedcardiovascularcomplicationsinclinicalpracticecurrentperspectives AT kowalczysanna cancertherapyrelatedcardiovascularcomplicationsinclinicalpracticecurrentperspectives AT mickiewiczagnieszka cancertherapyrelatedcardiovascularcomplicationsinclinicalpracticecurrentperspectives AT gruchałamarcin cancertherapyrelatedcardiovascularcomplicationsinclinicalpracticecurrentperspectives AT lewickaewa cancertherapyrelatedcardiovascularcomplicationsinclinicalpracticecurrentperspectives |